Your browser doesn't support javascript.
loading
Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
Kono, Koji; Mimura, Kousaku; Yamada, Reo; Ujiie, Daisuke; Hayase, Suguru; Tada, Takeshi; Hanayama, Hiroyuki; Min, Aung Kyi Thar; Shibata, Masahiko; Momma, Tomoyuki; Saze, Zenichirou; Ohki, Shinji.
Afiliación
  • Kono K; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. kojikono@fmu.ac.jp.
  • Mimura K; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Yamada R; Department of Advanced Cancer Immunotherapy, Fukushima Medical University, Fukushima, Japan.
  • Ujiie D; Department of Progressive DOHaD Research, Fukushima Medical University, Fukushima, Japan.
  • Hayase S; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Tada T; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Hanayama H; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Min AKT; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Shibata M; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Momma T; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Saze Z; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Ohki S; Department of Advanced Cancer Immunotherapy, Fukushima Medical University, Fukushima, Japan.
Esophagus ; 15(1): 1-9, 2018 01.
Article en En | MEDLINE | ID: mdl-29892809
ABSTRACT

BACKGROUND:

Immunotherapy has become a promising treatment strategy for cancer. Immune checkpoint blockade with anti-CTLA4 mAb and anti-PD-1 mAb has demonstrated clear evidence of objective responses including improved overall survival and tumor shrinkage, driving renewed enthusiasm for cancer immunotherapy in multiple cancer types including esophageal squamous cell carcinoma (ESCC). There are several clinical trials using anti-PD1 mAb for ESCC in early phases and the results are currently promising. RESULTS AND

CONCLUSIONS:

In this review, recent advances in cancer immunotherapy for ESCC are discussed with particular focus on immune checkpoint inhibitors and cancer vaccine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Inmunoterapia Límite: Humans Idioma: En Revista: Esophagus Año: 2018 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Inmunoterapia Límite: Humans Idioma: En Revista: Esophagus Año: 2018 Tipo del documento: Article País de afiliación: Japón